

# Prescription Enrollment Form

# Nerivio®

**Questions?**  
**Call the Nerivio Support**  
**Team: (937) 637-4846**

**Prescribers: Please complete this form in its entirety & attach Patient Face Sheet,  
then fax to: (888) 214-0258**

## PATIENT INFORMATION

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Sex: \_\_\_\_\_  
Address: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip Code: \_\_\_\_\_  
Cell Number: \_\_\_\_\_ E-mail: \_\_\_\_\_

## INSURANCE INFORMATION

Insurance Company: \_\_\_\_\_ Plan/Group Name: \_\_\_\_\_  
Member ID: \_\_\_\_\_ Group Number: \_\_\_\_\_  
Policyholder's Name: \_\_\_\_\_ Policyholder's DOB: \_\_\_\_\_

## PRESCRIBER INFORMATION

Prescriber Name: \_\_\_\_\_ Clinic: \_\_\_\_\_  
Clinic Address: \_\_\_\_\_ NPI: \_\_\_\_\_  
City: \_\_\_\_\_ State: \_\_\_\_\_ Zip Code: \_\_\_\_\_  
Office Contact: \_\_\_\_\_ Email: \_\_\_\_\_  
Primary Phone: \_\_\_\_\_ Fax Number: \_\_\_\_\_

## PRESCRIPTION INFORMATION

### Check the appropriate ICD-10 code (required):

☐ G43.001 ☐ G43.009 ☐ G43.011 ☐ G43.019 ☐ G43.101 ☐ G43.109 ☐ G43.111  
☐ G43.119 ☐ G43.701 ☐ G43.709 ☐ G43.711 ☐ G43.719 ☐ Other: \_\_\_\_\_

### Additional Clinical Information (Please check all that apply):

- ☐ Patients at risk of drug-drug interaction with other medications.  
☐ Pregnant women, women who are trying to conceive, or are breast-feeding.

### If applicable, check all acute and/or preventive treatments that have been tried.

- ☐ Triptans ☐ NSAIDS/oral analgesics ☐ Gepants ☐ Ditans ☐ Ergots ☐ Antiepileptics  
☐ Beta Blockers ☐ Monoclonal Antibodies ☐ Botox ☐ Antidepressants ☐ Other: \_\_\_\_\_

### Directions & Nerivio Quantity (required):

Set a strong, yet comfortable intensity level for each 45 min treatment.

**Acute:** 45 min treatment at onset of migraine. **1 Initial Fill + 12 Refill Units**

**Prevention:** 45 min treatment every other day, or as directed.

**Dual Use:** 45 min treatment every other day for prevention or at onset of migraine.

**1 Initial Fill + 12 Refill Units**

Additional Refill Qty: \_\_\_\_\_

**3 Initial Fills + 12 Refill Units**

Additional Refill Qty: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

## Nerivio prescriptions can be submitted to RISRx Pharmacy via your EMR or via FAX

### PRESCRIBING NERIVIO VIA YOUR ELECTRONIC MEDICAL RECORD (EMR) SYSTEM

1. Select "Retail" Pharmacy from your EMR search library by using the following criteria;

eRx Pharmacy Name: Pacific LTC Pharmacy	
NCPDP / NABP#	5664417
NPI #	1871002485
Phone (not for Rx or patient support): (949) 524-3566	
Address:	361 Hospital Rd. Suite 425 Newport Beach, CA 92663

2. In the notes section **MUST** include:

- a) "Nerivio"
- b) Number of Refills
- c) Diagnosis Code
- d) One of these instructions for use:
  - Acute: 45 minute treatment at onset of migraine
  - Prevention: 45 minute treatment every other day, or as directed
  - Dual Use: 45 minute treatment every other day for prevention **and/or** at onset of migraine

3. Attach patient demographic sheet to include:

- Any additional clinical criteria
- Chart notes from recent visits
- Medical Insurance information
- o If unable to locate the pharmacy/distributor in your search library, contact your EMR administrator or EMR software vendor and ask to have this pharmacy/distributor added to your system
- o **To reach the pharmacy directly regarding a specific prescription, please call 1 888-214-6693**
- o If you require additional assistance, please call Nerivio Cares at (937) 637-4846 or email at [support@nerivio.com](mailto:support@nerivio.com)

### PRESCRIBING NERIVIO VIA FAX

1. FAX the following to 1 888-214-0258

- The completed Nerivio Enrollment Form
- Patient demographic face sheet
- Chart notes from recent visits
- Medical insurance information
- o If you require additional assistance, or need a copy of the Nerivio Prescription Enrollment form, please call Nerivio Cares at (937) 637-4846 or email at [support@nerivio.com](mailto:support@nerivio.com)

**Nerivio**  
by theranica

Complete  
Migraine Care

## One Device for Effective Migraine Prevention and Treatment

Nerivio is a wearable migraine therapy that is safe and effective for preventing and treating migraine in patients ages 8 years and up.

### Preventing Migraine<sup>1</sup>

**4**  
**LESS**

Monthly  
Migraine  
Days




Over half  
of patients  
had a

**≥50%**  
reduction

in moderate  
to severe  
headache days.

### Acute Treatment of Migraine<sup>2</sup>

Adults at 2-hours Post Treatment



Clinical trials demonstrate that Nerivio provides consistent relief of pain and associated migraine symptoms, as well as significant reduction in monthly migraine days

Effective • Drug Free • Discreet • Wearable

Nerivio is safe and well tolerated with no systemic side effects or concern for medication overuse.

**Nerivio**  
by theranica

**57%**

of Adult Chronic patients achieved relief 2-hours post treatment with Nerivio.<sup>3,4</sup>


**72%**

of children<sup>5</sup> and adolescents<sup>6</sup> achieved pain relief 2-hours post treatment with Nerivio.

## Pivotal Acute RCT\* in Adult Episodic Patients<sup>2</sup>

(\* Randomized Controlled Trial)

Prospective, randomized, double-blind, placebo controlled, multi-center study (n=252)




After only one month, patients using Nerivio every other day showed a significant reduction in the number of migraine days per month.<sup>1</sup>

## Pivotal Prevention RTC\*

(\* Randomized Controlled Trial)

Prospective, randomized, double-blind, placebo controlled, multi-center study (n=248)



Significant reduction of MMD was reported in patients whether or not they were taking other preventive treatment in addition to Nerivio vs. placebo ( $p \leq 0.03$ ).

Of the 128 Nerivio patients studied, zero patients reported device related adverse events in the pivotal prevention trial.<sup>1</sup>

Scan here for clinical study info



1. Tepper SJ, et al. Remote electrical neuromodulation for migraine prevention: A double-blind, randomized, placebo-controlled clinical trial. Headache. 2023 Mar;63(3):377-389. doi: 10.1111/head.14469.
2. Yarnitsky D, et al. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache. 2019 Sep;59(8):1240-1252. doi: 10.1111/head.13551.
3. Nierenburg H, et al. Remote Electrical Neuromodulation for the Acute Treatment of Migraine in Patients with Chronic Migraine: An Open-Label Pilot Study. Pain Ther. 2020 Dec;9(2):531-543. doi: 10.1007/s40122-020-00185-1.
4. Grosberg B, et al. Safety and efficacy of remote electrical neuromodulation for the acute treatment of chronic migraine: an open-label study. Pain Rep. 2021 Oct 14;6(4):e966. doi: 10.1097/PR9.0000000000000966.
5. Werner K, et al. Acute treatment of migraine in children aged 6–11: Real-world analysis of remote electrical neuromodulation (REN). Annals of the Child Neurology Society. 2024 June;2(2): 135-145. doi.org/10.1002/cns3.20073.
6. Hershey AD, et al. Remote electrical neuromodulation for acute treatment of migraine in adolescents. Headache. 2021 Feb;61(2):310-317. doi.org/10.1111/head.14042.

Scan here for important safety info

